REGN Regeneron Pharmaceuticalsdata gap · 91% coverage
Health Care · Biotechnology · close $790.74 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Regeneron Pharmaceuticals (REGN) has a ThetaGrade House Rating of 61/100 (grade A), ranking #7 of 150 in Health Care. Its strongest pillars are cash flow (85) and profitability (81); its weakest is analyst sentiment (17). Data gap: 1 factor without usable data, so 91% of the method weight is covered. TTM revenue growth is 9.3% and operating margin 24.7%.
Data as of .
Data gap
No usable data for: 4Q gross-margin change. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 91% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · 17| Consensus score (1–5) (3.8%) | derived | 29 |
| 90-day net rating shift (3.8%) | derived | 29 |
Growth
weight 30.83% · 40| Revenue growth YoY (TTM) (12.3%) | 9.3% | 47 |
| EPS growth YoY (TTM) (12.3%) | 1.6% | 35 |
| Revenue acceleration (6.2%) | -2.3% | 36 |
Profitability
weight 18.5% · 81| Operating margin (18.5%) | 24.7% | 81 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% · 75| Net debt / EBITDA (9.9%) | -0.11× | 73 |
| Current ratio (4.9%) | 3.34 | 63 |
| Interest coverage (3.7%) | 87.74× | 94 |
Cash flow
weight 12.33% · 85| FCF margin (6.2%) | 28.4% | 90 |
| FCF yield (6.2%) | 5.0% | 79 |
Valuation
weight 12.33% · 68| P/E (inverted) (6.2%) | 19.58× | 83 |
| EV/Sales (inverted) (6.2%) | 5.20× | 52 |
Technicals (EOD)
| RSI(14) | 57.2 |
| EMA 9 / 21 | 769.58 / 768.53 · crossed up 1d ago |
| 200-day SMA | 735.42 |
| Volume vs 20d avg | 0.82× |
| 20-day return | 0.2% |
Exit-rule monitor
No exit or watch rules triggered.
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (us-gaap weighted basic shares, latest quarter (proxy)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like REGN's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is REGN's House Rating?
- REGN scores 61 out of 100 (grade A) as of 2026-10-16, ranking #7 of 150 Health Care stocks we cover.
- What do analysts say about REGN?
- ThetaGrade's analyst-sentiment pillar for REGN scores 17/100 against its sector peers, which we read as negative. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does REGN report earnings next?
- We do not have a reliable estimate for REGN's next earnings date (irregular SEC filing history); a rough window is 2026-10-28 to 2027-05-02. Check the company's investor-relations page.
- Is REGN a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology